Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-01-30

Clinical Trial Update: Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) [Phase 3]

View source ↗

Summary

Phase 3 trial of gantenerumab in early Alzheimer’s disease was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Gantenerumab (gantenerumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Alzheimer Disease | Phase 3 | Status: TERMINATED | Results posted: 2024-01-30